News and Press Releases
Press releases
Theralase® Announces Appointment of New Independent Director
Press ReleaseToronto, Ontario – June 6, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Phot...
Theralase® Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
Press ReleaseIn the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this press release. Toronto, Ontario – May 30 2023, Theralase® Technologies Inc. (“Theralase...
Theralase® Appoints Roger DuMoulin-White as President and Chief Executive Officer
Press ReleaseToronto, Ontario – May 24, 2023,Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo...
Theralase® Provides Update on Phase II Bladder Cancer Study
Press ReleaseFor the primary objective, 65% of Evaluable Patients (Patients evaluated by a Principal Investigator (“PI”)) achieved a Complete Response (“CR”) at any assessment date post primary Study Treatment and 30% of Evaluable Patients ac...
Theralase Releases FY2022 Audited Financial Statements
Press ReleaseToronto, Ontario – April 26, 2023, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Ph...
Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium
Press ReleaseToronto, Ontario – February 23, 2023,Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated ...
Theralase® Awarded TSX Venture 50 ™ Recognition as a Top Performing Company
Press ReleaseToronto, Ontario – February 21, 2023,Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting
Press ReleaseToronto, Ontario – February 2, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated ...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to Presented at the ASCO GU Cancer Symposium
Press ReleaseToronto, Ontario – January 25, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated ...
Theralase ® Announces Warrant Extension
Press ReleaseToronto, Ontario – January 5, 2023, Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dyna...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
